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Intragastric Balloons are  a temporary, reversible, and safer option compared to 
bariatric surgery  to promote significant weight loss leading to improved metabolic 
outcomes. However due to subsequent weight regain, alternative procedures are 
now preferred in adults. In adolescents , more amenable to lifestyle change, balloons 
may be an alternative to less reversible procedures. Our aim was to assess the 
tolerability and efficacy of the intragastric balloon in severely obese adolescents and 
the impact of associated weight loss on biomedical outcomes (glucose metabolism,  
blood pressure, lipid profiles) and bone density. A 2-year cohort study of 12 
adolescents (BMI >3.5 SD, Tanner stage >4) following 6 months intragastric balloon 
placement was carried out. Subjects underwent anthropometry, oral glucose 
tolerance test, and DEXA scans at 0, 6 and 24 months. 
Results showed clinically relevant improvements in blood pressure, insulin: glucose 
metabolism, liver function and sleep apnoea at 6 months. Changes were not 
sustained at 2 years though some parameters (Diastolic BP, HBA1c, insulin AUC) 
demonstrated longer-term improvement despite weight regain. Despite weight loss, 
bone mass accrual showed age appropriate increases. In conclusion, the intra-gastric 
balloon was safe, well tolerated and effective in supporting short-term weight loss 
and clinically relevant improvement in obesity related complications, which resolved 
in some individuals. Benefits were not sustained in the majority at 2 years. 
 
 
 
 
 
 
 
Article 
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A small proportion of children and adolescents have very severe obesity and 
develop obesity related complications in adolescence(1, 2).   
Such individuals tend to become obese adults with a consequent decrease in life 
expectancy of between 5-20 years(3). 
Bariatric surgery is effective in adolescents though as procedures have only 
relatively recently been undertaken in such populations data on longer term 
outcomes is lacking(4) In a recent UK single centre series of young adolescents, 
the average weight loss was 54kg with a reduction in BMI of 16.2 kg/m2 (5). 
Whilst NICE guidance makes provision for adolescent bariatric surgery in ǲexceptional circumstancesǳ(6) , there remains an understandable reluctance 
amongst paediatricians and commissioners to consider this.   
We undertook a pilot study to evaluate the effectiveness of intragastric balloons 
supported by a behavioural management programme in very severe adolescent 
obesity.  
Our premise was that adolescents are more amenable to lifestyle changes than 
adults and that the balloon supported by lifestyle intervention would ǲkickstartǳ 
weight loss and facilitate longer-term changes. 
Intra-gastric balloons (IGBs) have been used as an adjunct to weight loss for 30 
years (7). A review of adult studies reported a mean weight loss of 17.8 kg 
(range 4.9 - 28.5 kg, BMI change 4.0- 9.0 kg/m2), (30 studies, 4877 patients(8)) . 
The mortality rate was 0.07% (2 deaths in patients with previous gastric 
surgery). 
Minor side-effects were common with 8.6% of patients experiencing nausea and 
vomiting and 5% reporting abdominal discomfort (9).  Deflation or displacement 
of the balloon occurred in 2.5%, and obstruction in 0.8% of patients.   
©    2017 Macmillan Publishers Limited. All rights reserved.
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Only 2 studies examined weight loss a year after balloon removal. In one RCT, 
which included a sham treatment arm, weight loss after a year of balloon therapy 
was 21.3 kg (17.1% of total body weight). A year post balloon mean weight loss 
was 12.6 kg. (10).  
In adults IGBs are now used primarily in high anaesthetic risk patients prior to 
definitive bariatric procedures(11). Evidence that weight loss improves obesity 
related comorbidities is strong(12).In a retrospective study of 2500 IGB patients 
(mean BMI 44 kg/m2 ) rates of hypertension, diabetes and obstructive sleep 
apnoea (OSA)  improved(13).  
 There is concern that weight loss in childhood may reduce the accrual of bone 
mass that continues until 25 years. However, obese children have reduced bone 
density and an increased fracture risk(14).  Adult studies demonstrate decreased 
bone mass with both diet induced weight loss(15)and surgery(16). What 
happens following significant weight loss at time of peak bone mass accrual is 
unclear. 
The aim of our study was to examine longitudinally at 0, 6 and 24 months the 
impact of weight loss associated with IGB on 
  Co-morbidities such as glucose metabolism, blood pressure, lipids and 
liver enzymes 
  Developing skeleton by comparing change in fat mass and bone density 
 Psychosocial outcomes and physical activity (17) 
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A cohort of 12 severely obese adolescents (BMI SDS >3.5, Tanner stage ≥4) were 
recruited to an open, non-randomized, feasibility study .  Informed consent was 
taken.  
A detailed pre-balloon assessment included psychology, anthropometry, oral 
glucose tolerance test (OGTT) and DXA (lunar iDEXA) scans.  
Balloon Insertion 
Balloons were sited endoscopically under general anaesthetic and inflated with 
500ml saline stained with methylene blue to alert patients to balloon deflation. 
An antiemetic regimen of dexamethasone (single dose), cyclizine, ondansetron 
and buscapan was given intravenously initially and orally when tolerating fluids. 
All patients were discharged the following day on anti-emetics and 
antispasmodics. Lansoprazole was prescribed whilst the balloon was in situ to 
prevent gastric erosion/ulceration and to protect the balloon.  
Patients were advised a fully liquid diet in the first week post insertion with semi 
solids in the 2nd week and normal, healthy diet by week 3. Calories were not 
restricted to a set number. 
 
Statistical Considerations 
 
A sample of 12 patients was selected as the optimal size for a feasibility 
study(18). 
Results are expressed as means and standard deviations with 95% confidence 
interval (95% CI). Effect sizes for relationships were calculated using Pearsonǯs 
correlation co-efficient. 
Co-morbidities 
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Hypertension was defined as blood pressure >95th centile for age, sex and height. 
OSA was considered present if symptoms of sleep disordered breathing were 
reported or sleep study was abnormal. Mobility issues were as reported by 
participants. Insulin resistance was defined as a Homeostatic Metabolic 
Assessment score (HOMA) >4.4 or fasting hyperinsulinemia >120 pmol/l as per 
the OSCA (Obesity Services for Children and Adolescents) guidelines(19). 
Psychosocial issues were defined as ongoing child and adolescent mental health 
services (CAMHS) involvement. Liver function was considered abnormal if 
alanine transaminase (ALT) levels were twice upper limit of normal.  
Dyslipidemia was defined as in the OSCA guideline. (Cholesterol>5.2, TGL>1.47, 
HDL<1.09). 
Patient Demographics 
Twelve patients were recruited (5 males). 
Mean weight at baseline was 138.5 kg (SD ±23.9), BMI 46.4 kg/m2 (SD ±5.6) and 
BMI SDS +4.0 (SD ±0.3).  
 Patients had gained a mean of 11.1(±9.5) kg in the year prior to entering the 
study and a mean of 20.8 (±12.9) in the 2 years prior to entering the study.  
(The comorbidities within the cohort are detailed in Figure 1). One patient was 
on continuous positive airway pressure (CPAP) at night. 
Tolerability and complications: 
 
The balloon was well tolerated. All patients (except one) experienced nausea, 
vomiting and abdominal discomfort in the first week. One patient developed 
non-infective diarrhea 3 weeks after IGB insertion, which resolved 
spontaneously. One individual developed a subconjunctival hemorrhage 
(following vomiting). One patient was lost to follow-up after balloon removal due 
©    2017 Macmillan Publishers Limited. All rights reserved.
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to mental health problems (unrelated to the balloon). Another patient dropped 
out at 24 months. No serious complications (balloon deflation, intestinal 
obstruction) were seen and there were no early balloon removals. 
Weight loss 
 
Average weight loss at 6 months at balloon removal was 7.0 kg (p=0.005) with 
reduction in BMI of -2.53 kg/m2 (BMI SDS -0.2 SD (p=0.002). This represented a 
mean loss of 5% of initial body weight. However, weight loss was sustained in 
only 2 participants at 24 months.  
(Table 1 outlines the changes in anthropometric, biomedical and bone data 
during the study).  
Blood pressure 
 
Systolic and diastolic blood pressure (BP) fell by 5.8mmHg (SD16.8, p = 0.3) and 
2.0 mmHg (SD 10.9, p=0.6) respectively. Of the two patients with established 
hypertension, blood pressure normalized in one at 6 months. As patients 
regained weight after balloon removal, systolic and mean blood pressures 
subsequently rose and were above baseline levels at 24 months though diastolic 
BP remained below that at baseline. (Table1).  
 
Glucose and Insulin metabolism 
 
Insulin area under the curve (AUC) following OGTT improved at 6 months 
(p=0.05) though was not sustained at 2 years. HOMA scores also declined at 6 
months. Two of the 7 individuals with raised HOMA at balloon insertion had 
normal markers at balloon removal. Insulin AUC remained below pre 
intervention levels despite subsequent weight regain. There was also a fall in 
HBA1c at 6 months that was maintained despite weight regain (p=0.005).  
©    2017 Macmillan Publishers Limited. All rights reserved.
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There was an association between initial weight loss and improved insulin 
glucose metabolism (AUC insulin r=0.3, HBA1c r=0.4).  This association was 
stronger at 24 months (AUC insulin r=0.66 and HBA1c r=0.64) 
Lipid profiles 
 
Dyslipidemia did not resolve in the 6 individuals with baseline anomalies. 
Liver enzymes 
 
Of two with raised ALT at study inception, one improved but the other persisted. 
Gamma glutamyl transferase levels fell at 6 months (p=0.03) and remained 
below levels at baseline at 24 months. 
Obstructive sleep apnoea 
The patient on CPAP for sleep apnoea continued to lose weight at 24 months and 
was weaned off this. 
Bone 
 
Total percentage fat mass decreased -2.1%(CI -5.9,1.7, p<0.05) as did truncal fat 
mass percentage -2.1%(CI-4, -0.1, p<0.04) in the 6 months the balloon was in 
situ. However, there was no evidence that weight loss had a deleterious impact 
on bone with improved bone mineral density (BMD) and lumbar area and bone 
mineral content at 2 years. TBLH BMD Z score increased by 0.27 (CI -0.65,1.19, 
p=0.3) over the 2 years. (Table 1) 
 
This study demonstrated that the IGB was safe and well tolerated in young 
people. There were no early balloon removals. There was some initial nausea, 
vomiting and abdominal discomfort, but none of the more serious complications 
described in adult studies such as perforation, or obstruction were reported (9). 
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At 15.6 years participants were much younger than in adolescent cohorts 
reported previously. 
The magnitude of weight loss, (5% ) whilst  likely to be clinically significant, was 
lower than described in adult cohorts and in the minimal data available on 
younger patients (BMI reduction of 5 kg/m2 in Brazilian study versus 2.5 kg/m2 
in our cohort)(20).  However, stringent entry criteria in our study meant that all 
patients had to have undergone at least a three-month lifestyle intervention 
(Most had done substantially more than this) and pharmacotherapy (orlistat 
and/or sibutramine which was still licensed at that time. The study perhaps had 
a positive effect even for individuals with no/minimal weight loss when one 
considers that the cohort had gained an average of 20 kilos in the 2-years prior 
to the study. 
 
This was a feasibility study with limited numbers and therefore not powered to 
show statistical significance. There was considerable public patient involvement in study design who felt that recruitment to a Ǯstandardǯ care group for a randomized trial would have been difficult, as the young people felt ǲthere was nothing in it for them.ǳ However, one of the studies weaknesses is the lack of a 
control group, which may have shown more clearly the weight trajectories in a 
non-intervention group. Given the PPI concerns, a waiting list control cross over 
design in the setting of a larger study could be the next step in evaluating the 
efficacy of the intragastric balloons in obese adolescents.  
One key objective of the study was to ascertain whether rapid weight loss would 
adversely affect the developing skeleton as seen in adults(16). We demonstrated 
©    2017 Macmillan Publishers Limited. All rights reserved.
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that adolescents continued to demonstrate normal accrual of bone mass despite 
significant weight loss.  
 
At balloon removal, there were clinically relevant improvements in blood 
pressure, liver function and insulin glucose metabolism with successful 
resolution of co-morbidities in some subjects. Unfortunately, 8/ͳͲ individualǯs 
subsequently regained weight but a criterion for entry into the pilot was that 
individuals had been unsuccessful losing weight with previous lifestyle 
interventions. However there appeared to be a persisting benefit on diastolic BP, 
insulin AUC production and HBA1c  
In conclusion, the intra-gastric balloon is safe, well tolerated and effective 
supporting modest short-term weight loss. There was clinically important 
improvement in co-morbidities, albeit short-term in most instances. There was 
no detrimental effect on bone of rapid weight loss in adolescents. Whilst the 
technique was safe and effective, a larger RCT would be needed to fully evaluate 
clinical benefit and cost effectiveness. 
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Figure 1 Title Co-morbidities identified in severely obese children 
                 X axis Co-morbidity 
                 Y axis Number with Co-morbidity 
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Table 1: Table outlines the change in weight, BMI, blood pressure, insulin glucose 
metabolism, lipids, TBLH fat mass %, TBLH Bone mineral density, TBLH Bone area 
and Bone mineral content, Lumbar Bone mineral density, Bone area and Bone 
mineral content between baseline, balloon removal at 6 months and 2 years (18 
months after balloon removal) 
 
 Before 
Balloon 
insertion 
N=12 
Mean 
(±SDs) 
 After 
Balloon 
removal 
N=12 
Mean 
((±SDs) 
 
At 2 
years 
N=10 
Mean 
((±SDs) 
 
Mean 
difference 
between 
baseline 
and balloon 
removal at 
6 months 
(95 CI) 
[p value] 
Mean 
difference 
between 
baseline and 
24months 
(95 CI) 
      [p value] 
Body 
weight (kg) 
138.5 
(23.9) 
131.4 
(23.1) 
 
148.4 
(25.2) 
 
 
-7.1 
(-27,12.8) 
[p=0.005] 
+9.9 
(-11.8,31.8) 
[p=0.4] 
BMI 
(kg/m2) 
46.4 
(5.6) 
43.9 
(5.5) 
 
49.3 
(8.1) 
 
-2.5 
(-7.2,2.2) 
[p=0.004] 
+2.9 
(-3,8.8) 
[p=0.5] 
 
BMI SDS 4 
(0.3) 
3.8 
(0.3) 
 
4.2 
(0.5) 
 
-0.2 
(-0.37, -
0.03) 
[p=0.002] 
+0.2 
(-0.1,0.5) 
[p=0.5] 
Waist circumference 
(cm) 
128.3 
(19.1) 
115.9 
(15.6) 
 
138.7 
(21.2) 
 
-12.4 
(-27.2, 2.4) 
[p=0.016] 
+10.4 
(-6.7,27.5) 
[p=0.3] 
Systolic BP (mm of Hg) 127.8 
(11.9) 
122 
(16) 
 
132.2 
(18.3) 
 
-5.8 
(-17.7,6.1) 
[p=0.3] 
+4.4 
(-9.1, 17.1) 
[p=0.5] 
Diastolic BP (mm of Hg) 74.8 
(5.4) 
72.8 
(9.5) 
 
72(7.5) 
 
-2.0 
(-8.5,4.5) 
[p=0.6] 
-2.8 
(-8.3, 2.3) 
[p=0.2] 
 
Fasting glucose (mmol) 4.3 
(0.3) 
4.3 
(0.3) 
 
4.7 
(0.4) 
 
-0.03 
(-0.25,0.25) 
[p=0.5] 
+0.4 
(0.1,0.7) 
[p=0.1] 
Fasting 
Hyperinsulinemia(pmol/l) 
209.6 
(141.6) 
189 
(116.4) 
 
213.6 
(106.4) 
 
-20.6 
(-130.3,89) 
[p=0.3] 
+4 
(109.4,117) 
[p=0.8] 
      HOMA IR       6.6 
(4.7) 
 
        5.2 
(3.2) 
 
    7.4 
(3.8) 
 
       -1.4 
(-4.8,2) 
[p=0.5] 
          +0.8 
(-3.1,4.7) 
[p=0.6] 
Insulin (AUC)(pmol/l) 3387 
(2417) 
 
2173 
(1845) 
2780 
(2588) 
 
-1214 
(3034,606) 
[p=0.05] 
-607 
(-2835,1621) 
[p=0.4] 
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ALT 47.3 
(25.6) 
43 
(23.8) 
 
48.8 
(28.7) 
 
-4.3 
(-25.2,16.6) 
[p=0.4] 
+1.5 
(-22.7, 25.7) 
[p=0.7] 
Gamma GT 32.9 
(13.1) 
25.8 
(9.5) 
 
29.4 
(12.5) 
 
-7.1 
(-16.8, 2.6) 
[p=0.03] 
-3.5 
(-15,8) 
[p=0.3] 
Cholesterol 4.4 
(0.7) 
4.1 
(0.6) 
 
4.3 
(0.8) 
 
-0.3 
(-0.85,0.25) 
[p=0.2] 
-0.1 
(-0.8,0.6) 
[p=0.4] 
Triglycerides 1.5 
(0.7) 
1.9 
(0.8) 
 
1.3 
(0.6) 
 
+0.4 
(-0.24,1.04) 
[p=0.1] 
-0.2 
(-0.8,0.4) 
[p=0.4] 
HBA1c 
(mmol/mol) 
36.2 
(2.5) 
35.1 
(1.8) 
 
34.1 
(2) 
 
-1.1 
(-2.9,0.7) 
[p=0.08] 
-2.1 
(-4.1,-0.1) 
[p=0.005] 
TBLH fat mass 
% 
54.9 
(3.5) 
52.8 
(5.2) 
54.9 
(7.5) 
-2.1 
(-5.9,1.7) 
[p<0.05] 
0.0 
(-5.0,5.0) 
[p=0.5] 
TBLH BMD 
(g/cm2) 
1.15 
(0.07) 
1.15 
(0.06) 
1.19 
(0.08) 
0.002 
(-0.03, 
0.03) 
[p=0.9] 
0.04 
(0.01, 0.06) 
   [p=0.01] 
 
TBLH BMD z score 1.7 
(1) 
1.64 
(0.9) 
1.97 
(1.1) 
-0.06 
(-0.9,0.7) 
[p=0.3] 
 
0.27 
(-0.65,1.19) 
[p=0.3] 
 
TBLH BA 
(cm2) 
2010.2 
(240.7) 
2056.5 
(205.3) 
1958.3 
(252.8) 
46.4 
(-15.8,108) 
[p=0.13] 
-22.5 
(-97.5, 52.5) 
[p=0.52] 
TBLH BMC 
(gm) 
2307.9 
(287.6) 
2368.6 
(254.1) 
2343.9 
(334.5) 
60.7 
(5.5, 115.9) 
[p=0.03] 
43.9 
(-20.6, 108.4) 
[p=0.16] 
L1-L4 BMD(g/cm2) 1.23 
(0.2) 
1.26 
(0.2) 
1.28 
(0.2) 
0.03 
(0.01, 0.04) 
      [p=0.01] 
0.04 
(-0.02, 0.10) 
[p=0.14] 
L1-L4 BMD z score 0.9 
(1.2) 
0.87 
(1.2) 
0.76 
(1.3) 
-0.03 
(-1.09,1.03) 
[p=0.6] 
-0.14 
(-1.26,0.98) 
[p=0.6] 
L1-L4 BA(cm2) 57.4 
(7.6) 
58.1 
(7.5) 
58.8 
(7.1) 
0.8 
(0.4, 1.2) 
[p=0.002] 
2.0 
(0.9, 3.0) 
[p=0.003] 
L1-L4 BMC(gm) 70.5 
(13.0) 
73.0 
(13.3) 
75.6 
(14.0) 
2.5 
(1.4, 3.6) 
[p=0.001] 
5.3 
(1.0, 9.5) 
[p=0.02] 
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Key  
 
TBLH Total body less head 
BMC   Bone mineral content 
BA      Bone area 
BMD Bone mineral density 
 
Reference population used to calculate the BMI z score was based on the 
UK90 growth charts  
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Figure 1: The frequencies of key co-morbidities identified in the cohort are 
illustrated. All had a least one comorbidity and several patients had multiple 
comorbidities 
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